What are the recommended medications and dosages for treating allergic rhinitis in an 18-year-old male?

Recommended Medications and Dosages for Allergic Rhinitis in an 18-Year-Old Male

Start with an intranasal corticosteroid as first-line monotherapy, specifically fluticasone propionate 200 mcg (2 sprays per nostril) once daily, which is the most effective single agent for controlling all four major symptoms of allergic rhinitis including nasal congestion. 1, 2

Treatment Algorithm Based on Severity

For Mild-to-Moderate Symptoms

• Intranasal corticosteroid (INCS) monotherapy:

  • Fluticasone propionate 200 mcg/day (2 sprays per nostril once daily)
  • Mometasone furoate 200 mcg/day (2 sprays per nostril once daily)
  • Budesonide 256 mcg/day (2 sprays per nostril once daily)

  These are the most effective medications for all nasal symptoms including congestion, with onset of action within 12 hours (though full benefit may take several days) 1

For Moderate-to-Severe Symptoms or Inadequate Response to INCS Alone

Combination therapy with intranasal corticosteroid PLUS intranasal antihistamine:

• Fluticasone propionate 200 mcg + azelastine 548 mcg (available as fixed-combination spray, 1-2 sprays per nostril twice daily)

This combination provides approximately 40% greater symptom reduction compared to either agent alone and is particularly effective for patients with moderate-to-severe disease 2

Alternative Options (Listed in Order of Preference)

Second-Line: Oral Second-Generation Antihistamines

If patient refuses intranasal therapy or for episodic/intermittent symptoms:

• Cetirizine 10 mg once daily
• Loratadine 10 mg once daily
• Desloratadine 5 mg once daily
• Fexofenadine 180 mg once daily

These are less effective than INCS, particularly for nasal congestion, but appropriate for PRN use due to rapid onset of action 1

Third-Line: Leukotriene Receptor Antagonist

• Montelukast 10 mg once daily at bedtime

This is less effective than INCS but may be preferred by patients who don't tolerate intranasal medications. Consider if concurrent asthma is present 2

Adjunctive Therapy for Specific Symptoms

For prominent nasal congestion (short-term use only):

• Oral decongestant: Pseudoephedrine 60 mg every 4-6 hours (maximum 240 mg/day)
• Can be combined with antihistamines but monitor for insomnia, irritability, palpitations 1

For severe rhinorrhea:

• Ipratropium bromide nasal spray 0.03% (2 sprays per nostril 2-3 times daily)
• Reduces rhinorrhea specifically but not other symptoms 1

Critical Dosing Instructions

Intranasal Corticosteroid Technique

• Direct spray away from nasal septum to prevent irritation and bleeding
• Use continuously for seasonal allergic rhinitis (not just PRN) for maximum efficacy
• Onset typically within 12 hours, but may take up to several days for full benefit 1

Intranasal Antihistamine Considerations

• Rapid onset of action (within minutes), making it appropriate for PRN use
• Side effects include bitter taste (2-13% of patients) and mild somnolence
• When used in combination with INCS, provides additive benefit 2

Important Caveats and Pitfalls

Avoid these common mistakes:

1. Do NOT use topical decongestants (oxymetazoline, phenylephrine) for more than 3 days due to risk of rhinitis medicamentosa (rebound congestion) 1

2. Do NOT use oral corticosteroids routinely - reserve short courses (5-7 days only) for very severe, intractable symptoms. Never use intramuscular depot corticosteroids 1

3. Do NOT use first-generation antihistamines (diphenhydramine, chlorpheniramine) as they cause sedation and performance impairment that patients may not perceive 1

4. Continuous daily use is more effective than PRN use for seasonal or perennial allergic rhinitis, except for intranasal antihistamines which work rapidly 1

Evidence Hierarchy

The 2017 Joint Task Force guidelines 2 represent the most recent high-quality evidence, showing that:

• INCS remains the most effective monotherapy
• Combination INCS + intranasal antihistamine provides clinically meaningful additional benefit for moderate-to-severe disease (though this is a weak recommendation due to cost considerations)
• Montelukast is definitively less effective than INCS but acceptable for patients who refuse intranasal therapy

The 2024-2025 ARIA guidelines 3 further support the use of INAH+INCS combination over either agent alone, particularly for patients with inadequate control on monotherapy.

For this 18-year-old male, start with fluticasone propionate 200 mcg once daily, and escalate to combination therapy with azelastine if symptoms remain uncontrolled after 1-2 weeks. 2